Literature DB >> 16983659

Striatal specificity of gene expression dysregulation in Huntington's disease.

Elizabeth A Thomas1.   

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder caused by an expanded CAG repeat region in exon 1 of the HD gene. This mutation results in the presence of an abnormally long polyglutamine tract in the encoded protein, huntingtin (htt). A major question in this field is how the mutant htt protein, which is expressed ubiquitously throughout the brain and body, causes severe neuropathologic changes predominantly in the striatum. The mechanisms accounting for this specificity are unknown. The role of transcriptional dysregulation in the pathophysiology of HD has gained much attention in recent years, however, this theory has been unable to explain the specificity of dysfunction and degeneration in HD. Microarray studies have showed hundreds of gene expression changes in mouse models of HD and in post-mortem brain samples from HD subjects. Among the genes whose expression levels are preferentially altered are those that exhibit enriched expression in the striatum, which we have argued are the most relevant to disease pathology. These "striatal-enriched" genes are associated with several systems previously implicated in HD pathology, especially disturbances in transcriptional processes and calcium homeostasis. Large-scale changes in striatal gene expression in this manner would likely have particularly devastating effects to normal striatal function and could explain the specificity of striatal dysfunction and ultimate neurodegeneration observed in HD. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16983659     DOI: 10.1002/jnr.21046

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  28 in total

Review 1.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

2.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Bin Tang; Alexandre Kuhn; SoongHo Kim; Daniel H Geschwind; Timothy B Brown; Ruth Luthi-Carter; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2010-12-20       Impact factor: 6.150

3.  Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

Authors:  Haiqun Jia; Judit Pallos; Vincent Jacques; Alice Lau; Bin Tang; Andrew Cooper; Adeela Syed; Judith Purcell; Yi Chen; Shefali Sharma; Gavin R Sangrey; Shayna B Darnell; Heather Plasterer; Ghazaleh Sadri-Vakili; Joel M Gottesfeld; Leslie M Thompson; James R Rusche; J Lawrence Marsh; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2012-05       Impact factor: 5.996

4.  Huntington's disease pattern of transcriptional dysregulation in the absence of mutant huntingtin is produced by knockout of neuronal GLT-1.

Authors:  Robert B Laprairie; Geraldine T Petr; Yan Sun; Kathryn D Fischer; Eileen M Denovan-Wright; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2018-04-27       Impact factor: 3.921

5.  Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.

Authors:  Paula A Desplats; James R Lambert; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2008-05-22       Impact factor: 5.996

6.  High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntington's disease CAG knock-in mice across multiple genetic backgrounds.

Authors:  Seth A Ament; Jocelynn R Pearl; Andrea Grindeland; Jason St Claire; John C Earls; Marina Kovalenko; Tammy Gillis; Jayalakshmi Mysore; James F Gusella; Jong-Min Lee; Seung Kwak; David Howland; Min Young Lee; David Baxter; Kelsey Scherler; Kai Wang; Donald Geman; Jeffrey B Carroll; Marcy E MacDonald; George Carlson; Vanessa C Wheeler; Nathan D Price; Leroy E Hood
Journal:  Hum Mol Genet       Date:  2017-03-01       Impact factor: 6.150

Review 7.  Mutant huntingtin and mitochondrial dysfunction.

Authors:  Ella Bossy-Wetzel; Alejandra Petrilli; Andrew B Knott
Journal:  Trends Neurosci       Date:  2008-10-24       Impact factor: 13.837

Review 8.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

9.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

10.  The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Paula A Desplats; Bin Tang; Elisabetta Soragni; Ryan Burnett; Fuying Gao; Kelsey M Fitzgerald; Jenna F Borok; David Herman; Daniel H Geschwind; Joel M Gottesfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.